注射用生物製藥市場 - 技術，治療，市場，策略，預測

Injectable Biological Drugs - Technologies, Therapeutics, Markets, Strategies & Forecasts

出版日期: 2025年01月30日 | 出版商:

Greystone Research Associates | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

按藥物類別劃分，生物製劑在開發和臨床試驗中繼續超過所有其他新化學實體。由於生物製劑通常針對慢性病，因此必須制定劑量策略和治療方案以承受長期使用，並且通常由可能受到與其醫療狀況直接相關的限制的患者自行開發。抗體、荷爾蒙、酵素和其他生物製劑的強大生理效應也推動了對安全性和依從性的需求。設備設計人員和藥物開發人員之間的合作發生在藥物開發週期的早期，通常允許設備設計以匹配特定藥物治療的生物利用度目標和藥物動力學特徵。目前正在開發的新型注射輸送裝置設計可能為替代注射方法創造新的機會。設備供應商和製藥公司之間的合作有望加速市場對許多新興療法的新型注射設備的接受，包括治療性疫苗、基於 DNA 的藥物和蛋白質衍生的生物製劑。

報告價值矩陣

本報告提供注射用生物製藥市場相關調查，彙整市場概要，以及患者的未滿足需求等的市場機會，生技藥品的藥物輸送的課題與限制，各類藥物的產品分析，及的加入此市場的主要企業的簡介等資訊。

"Injectable Biological Drugs: Technologies, Therapeutics, Markets, Strategies and Forecasts" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injection devices for administering biologicals. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

New Platforms for Biological Drug Delivery

Biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones, enzymes and other biological drugs also increase the need for safety and adherence. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies. New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.

Report Value Matrix

What You Will Learn:

What are the product and user requirements that drive the biological drug-device selection process?
What are the essential design factors, technologies and market development issues for injection devices capable of administering biological dugs?
What is the impact of development-stage biological manufacturing process changes on device go-to-market readiness and how has it changed in recent years?
How do device selection decisions align across biological drug classes? Therapeutic targets? Market segments?
What is the impact of drug-device dependencies on pre- and post-marketing product life cycle management?
What are the significant economic, technology, and regulatory factors affecting the market for biological drug injection devices?